home / stock / bbio / bbio quote
Last: | $ |
---|---|
Change Percent: | -0.55% |
Open: | $35.05 |
Close: | $34.65 |
High: | $35.07 |
Low: | $33.77 |
Volume: | 249,717 |
Last Trade Date Time: | 02/12/2020 04:42:27 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $35.05 | $34.65 | $35.07 | $33.77 | 249,717 | 02-12-2020 |
$ | $36.83 | $34.84 | $37.5999 | $34.57 | 452,375 | 02-11-2020 |
$ | $35.04 | $36.23 | $36.26 | $34.951 | 290,193 | 02-10-2020 |
$ | $35.39 | $34.995 | $35.90 | $34.85 | 398,885 | 02-07-2020 |
$ | $35.46 | $35.40 | $35.97 | $34.79 | 458,023 | 02-06-2020 |
$ | $34.93 | $35.00 | $35.49 | $34.48 | 326,803 | 02-05-2020 |
$ | $35.00 | $34.50 | $35.20 | $34.18 | 455,467 | 02-04-2020 |
$ | $34.63 | $34.81 | $35.35 | $34.20 | 335,303 | 02-03-2020 |
$ | $34.77 | $34.49 | $34.94 | $33.25 | 281,971 | 01-31-2020 |
$ | $34.03 | $34.93 | $35.4676 | $33.01 | 293,618 | 01-30-2020 |
$ | $34.26 | $34.24 | $35.08 | $33.23 | 256,799 | 01-29-2020 |
$ | $35.00 | $34.26 | $35.057 | $33.67 | 267,492 | 01-28-2020 |
$ | $34.00 | $34.80 | $35.21 | $34.00 | 326,593 | 01-27-2020 |
$ | $34.45 | $34.13 | $35.13 | $33.87 | 500,033 | 01-24-2020 |
$ | $33.95 | $34.39 | $35.00 | $33.01 | 260,858 | 01-23-2020 |
$ | $32.38 | $34.16 | $34.90 | $32.2401 | 332,289 | 01-22-2020 |
$ | $34.21 | $32.23 | $34.45 | $31.28 | 594,825 | 01-21-2020 |
$ | $35.33 | $34.40 | $35.63 | $34.00 | 236,298 | 01-20-2020 |
$ | $35.33 | $34.40 | $35.63 | $34.00 | 234,945 | 01-17-2020 |
$ | $34.90 | $35.00 | $35.50 | $34.47 | 593,560 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biop...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pres...
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM part...